The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer
Clinical trial NCT06959589 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06959589
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-22
- Primary completion
- 2027-05-31
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.